Wire Stories
PharmaEssentia Completes Patient Enrollment for Phase 2b EXCEED-ET Trial in Essential Thrombocythemia and Phase 3b ECLIPSE-PV Trial in Polycythemia Vera
Both trials, EXCEED-ET and ECLIPSE-PV, completed enrollment at 142% and 110% of target, respectively, demonstrating high levels of clinical site interest BURLINGTON,...